+87.4%
ARKK vs MRNA
+34.8%
+52.6%
-39.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.6% | +5.4% | -4.8% | +0.1% |
| 7D | -3.1% | -1.1% | -2.0% | -3.0% |
| 30D | +2.7% | +126.1% | -123.4% | -11.5% |
| 3M | +10.8% | +190.0% | -179.3% | -11.0% |
| 6M | +14.4% | +157.2% | -142.8% | -5.9% |
| YTD | +8.7% | +388.2% | -379.5% | -23.9% |
| 1Y | +6.7% | +467.0% | -460.3% | -28.7% |
| 3Y | +87.4% | +36.1% | +51.3% | +49.3% |
| All | +87.4% | +34.8% | +52.6% | +49.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling